Dr Reddy’s plans to launch generic semaglutide in March 2026, potentially lowering prices in India’s fast-growing weight-loss drug market dominated by Wegovy and Mounjaro
India’s fast-growing anti-obesity drug market may be headed for major pricing shake-up, with Dr Reddy’s Laboratories preparing to launch a generic version of semaglutide in March 2026 following patent expiry.
If executed aggressively on pricing, the move could materially lower treatment costs in a segment currently dominated by imported blockbuster brands such as Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro.
A blockbuster category built in months
The past year has transformed India’s metabolic therapy landscape.
Eli Lilly’s Mounjaro (tirzepatide), a dual GIP and GLP-1 receptor agonist, was launched in India on March 20, 2025, for obesity, overweight and Type 2 diabetes. Positioned as a high-efficacy therapy, it quickly gained traction among endocrinologists and obesity specialists.
Within months of launch, Mounjaro became the highest-selling drug in India, clocking sales of over Rs 496 crore. Initially introduced in vial format priced roughly between Rs 3,500 and Rs 4,375 depending on dosage, Lilly subsequently rolled out its KwikPen format to improve convenience and drive accessibility.
Novo Nordisk entered the fray in June 2025 with Wegovy (semaglutide), intensifying competition in what has become one of the fastest-growing therapy areas. Cipla, under a partnership with Eli Lilly, also launched its tirzepatide brand Yurpeak, widening availability.
High demand, limited affordability
India has one of the largest populations globally living with obesity and Type 2 diabetes. Urbanisation, sedentary lifestyles and dietary shifts have pushed metabolic disorders to the forefront of public health concerns.
Physicians report rising demand not just from diabetics but also from younger, urban patients seeking structured medical weight management. However, high monthly therapy costs—running into several thousand rupees—have limited penetration largely to metros and higher-income groups.
Insurance coverage for obesity treatment remains patchy, and out-of-pocket spending dominates.
The generics inflection point
That is where Dr Reddy’s planned March 2026 entry becomes significant.
Semaglutide, the active ingredient in Wegovy, will open up to generic competition after patent expiry. Dr Reddy’s, with its strong track record in complex generics and injectables, is expected to leverage domestic manufacturing scale and distribution strength to compete aggressively.
“The presence of lower-cost semaglutide will definitely help more and more patients access this medicine. Currently, patients are trying to use higher-cost versions with what I would call ‘Jugaad’ techniques—micro-dosing the pen, taking lesser doses on a standard pen, or taking it less frequently,” Dr. Subramanian Kannan, Director – Endocrinology and Diabetology at Narayana Health City, Bengaluru, said.
“The effects of these kinds of practices are not known, and we hope that lower-cost semaglutide will help more patients be able to take GLP-1s safely and benefit from them,” he said.
Historically, once patents expire and Indian drugmakers enter a high-value segment, competition intensifies rapidly. In a price-sensitive market like India, the arrival of multiple generics typically leads to noticeable cost rationalisation and wider patient access over time.
Ripple effects on innovator brands
While generic semaglutide will directly challenge Wegovy, the pricing reset could have spillover effects on tirzepatide as well.
Mounjaro currently enjoys strong brand recall and clinical positioning owing to its dual-action mechanism.
However, in a price-sensitive market, a significantly cheaper semaglutide alternative could influence prescribing decisions, particularly if efficacy differences are perceived as marginal for certain patient groups.
End of Article